治疗定植金黄色葡萄球菌的家长对新生儿重症监护室传播的影响:随机临床试验
该双盲随机临床试验在巴尔的摩两个三级NICU纳入236名有金黄色葡萄球菌定植家长的新生儿,比较家长经鼻莫匹罗星联合2%氯己定擦拭布与安慰剂对新生儿获得同源菌株定植的影响。结果显示干预组14.6% vs 安慰剂组28.7%发生同源定植(风险差-14.1%,HR 0.43),任何菌株定植亦降低(31.4% vs 45.5%,HR 0.57),但需进一步验证。
要点
- 家长鼻腔莫匹罗星+氯己定擦拭可降低新生儿同源金葡菌定植(14.6% vs 28.7%)。
- 干预亦降低新生儿获得任何金葡菌菌株的风险(31.4% vs 45.5%,HR 0.57)。
- 家长皮肤反应常见(干预4.8%,安慰剂6.2%),需权衡利弊。
核心结论
- 在初步试验中,治疗定植家长可显著减少新生儿与家长基线菌株同源的金葡菌定植。
- 需进一步研究重复这些发现并评估其普遍性。
研究设计与样本
- 纳入236名有金葡菌定植家长的新生儿,家长随机接受经鼻莫匹罗星+2%氯己定擦拭布(n=117)或安慰剂(n=119)治疗5天。
- 主要终点为90天内同源金葡菌定植,定义为新生儿获得的菌株与筛查时家长菌株相同。
主要发现
- 190名新生儿纳入分析,74名(38.9%)在90天内获得金葡菌定植,其中42名(56.8%)为同源菌株。
- 干预组13/89(14.6%) vs 安慰剂组29/101(28.7%)发生同源定植,风险差-14.1%(95%CI -30.8%至-3.9%),HR 0.43(95.2%CI 0.16至0.79)。
- 干预组28/89(31.4%) vs 对照组46/101(45.5%)获得任何金葡菌菌株,HR 0.57(95%CI 0.31至0.88)。
- 干预组1例(1.1%)、对照组1例(1.0%)在定植前发生金葡菌感染。
- 家长皮肤反应:干预组4.8%,安慰剂组6.2%。
临床怎么用
- 对于NICU中金葡菌定植家长,可考虑经鼻莫匹罗星联合氯己定擦拭以减少新生儿同源定植。
- 需注意家长皮肤反应,并告知该策略为初步证据,需进一步验证。
局限性
- 为初步试验,需进一步研究重复发现并评估普遍性。
- 208名随机新生儿中18名失访,最终190名纳入分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Staphylococcus aureus is a leading cause of health care-associated infections in the neonatal intensive care unit (NICU). Parents may expose neonates to S aureus colonization, a well-established predisposing factor to invasive S aureus disease. OBJECTIVE: To test whether treating parents with intranasal mupirocin and topical chlorhexidine compared with placebo would reduce transmission of S aureus from parents to neonates. DESIGN, SETTING, AND PARTICIPANTS: Double-blinded randomized clinical trial in 2 tertiary NICUs in Baltimore, Maryland. Neonates (n = 236) with S aureus-colonized parent(s) were enrolled. The study period was November 7, 2014, through December 13, 2018. INTERVENTIONS: Parents were assigned to intranasal mupirocin and 2% chlorhexidine-impregnated cloths (active treatment, n = 117) or petrolatum intranasal ointment and nonmedicated soap cloths (placebo, n = 119) for 5 days. MAIN OUTCOMES AND MEASURES: The primary end point was concordant S aureus colonization by 90 days, defined as neonatal acquisition of an S aureus strain that was the same strain as a parental strain at time of screening. Secondary outcomes included neonatal acquisition of any S aureus strain and neonatal S aureus infections. RESULTS: Among 236 randomized neonates, 208 were included in the analytic sample (55% male; 76% singleton births; mean birth weight, 1985 g [SD, 958 g]; 76% vaginal birth; mean parent age, 31 [SD, 7] years), of whom 18 were lost to follow-up. Among 190 neonates included in the analysis, 74 (38.9%) acquired S aureus colonization by 90 days, of which 42 (56.8%) had a strain concordant with a parental baseline strain. In the intervention and placebo groups, 13 of 89 neonates (14.6%) and 29 of 101 neonates (28.7%), respectively, acquired concordant S aureus colonization (risk difference, -14.1% [95% CI, -30.8% to -3.9%]; hazard ratio [HR], 0.43 [95.2% CI, 0.16 to 0.79]). A total of 28 of 89 neonates (31.4%) in the intervention group and 46 of 101 (45.5%) in the control group acquired any S aureus strain (HR, 0.57 [95% CI, 0.31 to 0.88]), and 1 neonate (1.1%) in the intervention group and 1 neonate (1.0%) in the control group developed an S aureus infection before colonization. Skin reactions in parents were common (4.8% intervention, 6.2% placebo). CONCLUSIONS AND RELEVANCE: In this preliminary trial of parents colonized with S aureus, treatment with intranasal mupirocin and chlorhexidine-impregnated cloths compared with placebo significantly reduced neonatal colonization with an S aureus strain concordant with a parental baseline strain. However, further research is needed to replicate these findings and to assess their generalizability. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02223520.
引用
- Milstone AM, Voskertchian A, Koontz DW, et al. Effect of Treating Parents Colonized With Staphylococcus aureus on Transmission to Neonates in the Intensive Care Unit: A Randomized Clinical Trial. JAMA. 2020. PMID: 31886828. doi:10.1001/jama.2019.20785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。